iSERA Lifesciences submitted its monitoring agency report for the quarter ended June 30, 2026, to the Bombay Stock Exchange on August 14, 2026. The filing details the utilization of proceeds from its rights issue of equity shares, which raised an aggregate amount of ₹8.08 crore. Infometrics Valuation and Rating Limited served as the monitoring agency for the issue.

The company utilized ₹1.15 crore of the net proceeds during the first quarter of FY27. This expenditure was allocated across three primary heads: financing working capital requirements, general corporate purposes, and issue-related expenses. As of the end of the quarter, ₹6.26 crore remained unutilized.

Utilization Breakdown

The deployment of funds aligns with the objects specified in the letter of offer dated October 16, 2025. The statutory auditor, GMKS & Co Chartered Accountants, verified the details and confirmed no deviations from the disclosed expenditures.

Note: Issue-related expenses were incurred prior to this quarter or are yet to be fully booked in this period's utilization summary as per the report structure.

Working Capital and Corporate Expenses

The company directed ₹0.93 crore towards financing working capital requirements. These funds were used to meet operational and administrative expenses, supporting the company’s technology-enabled services model which involves longer receivable cycles. An additional ₹0.22 crore was deployed for general corporate purposes, specifically towards securing new office premises as outlined in the offer document.

Deployment of Unutilized Proceeds

The unutilized balance of ₹6.26 crore has been parked in fixed deposits and current accounts to preserve capital while awaiting further deployment. The majority of these funds are invested in fixed deposits with Kotak Mahindra Bank.

What the Numbers Show

The slow burn rate of the rights issue proceeds indicates a conservative approach to capital deployment in the immediate post-issue period. With only 14% of the total raised capital utilized in the first quarter, the company retains significant financial flexibility. The concentration of unutilized funds in short-term fixed deposits earning between 5.25% and 5.50% suggests a focus on liquidity preservation rather than immediate aggressive expansion or capex execution.

Regulatory Compliance

The filing was made pursuant to Regulation 82 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, read with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The monitoring agency declared that there were no material deviations from the objects of the issue and no change in the means of finance. The Board of Directors approved the revised timeline for fund utilization via resolution dated April 22, 2026, citing strategic realignment and administrative lead times.

iSERA Lifesciences reported a standalone net loss of ₹33.62 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a significant deterioration from the ₹54.98 lakh profit posted in the preceding quarter. The company recorded zero revenue from operations and zero other income during the period, resulting in a complete absence of top-line growth. Total expenses for the quarter amounted to ₹33.62 lakh, leading to a basic earnings per share (EPS) of ₹(1.60), compared to ₹1.58 in Q4FY26.

The Board of Directors, including Managing Director Jayshree Suresh Jain, approved the unaudited financial results on August 7, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the independent auditor, G M K S & Co, Chartered Accountants, in accordance with Standard on Review Engagements (SRE 2410). The company operates in the IT/ITES sector and has no separate reportable segments under Ind AS-108.

Financial Performance

The financial statement highlights a stark contrast between the current quarter and the previous period. While iSERA Lifesciences generated ₹116.18 lakh in revenue from operations in Q4FY26, this figure dropped to nil in Q1FY27. Other income also ceased, falling from ₹5.77 lakh to zero. Despite the lack of revenue, the company incurred expenses totaling ₹33.62 lakh.

What the Numbers Show

The most critical aspect of this filing is the divergence between revenue generation and cost structure. In Q4FY26, the company maintained a positive operating margin with revenues significantly outpacing expenses. In Q1FY27, the cessation of revenue operations did not lead to a proportional reduction in costs. "Other Expenses" remained substantial at ₹31.31 lakh, accounting for nearly 93% of total quarterly outflows. This suggests that fixed or semi-fixed operational costs continue to be incurred despite the lack of business activity, eroding the reserves which now stand at ₹(49.81) lakh, a deterioration from ₹(16.19) lakh at the end of FY26. The paid-up equity share capital remains unchanged at ₹840.90 lakh.